Table 2.
Bivariate analyses by client's geographical residence region (n=187)
| Rural | Suburban | Urban | ||
|---|---|---|---|---|
| n=53 | n=37 | n=97 | ||
| Mean/% | Mean/% | Mean/% | p | |
| Percent of sample | 28.3% | 19.8% | 51.9% | |
| Geographic discordance | 24.5% | 8.1% | 1.0% | <.001 |
| Treatment Center Characteristics | ||||
| Offers a residential level of care | 67.9% | 94.6% | 100.0% | <.001 |
| Average daily census of treatment center | 69.9 | 41.7 | 146.9 | <.001 |
| Socio-demographics | ||||
| Age | 30.7 | 28.4 | 31.8 | .121 |
| Female | 54.7% | 62.2% | 56.7% | .773 |
| White | 96.2% | 89.2% | 93.8% | .404 |
| High School Diploma | 73.6% | 78.4% | 67.0% | .386 |
| Married | 26.4% | 16.2% | 10.3% | .037 |
| Employed full/part-time | 15.1% | 18.9% | 15.5% | .866 |
| Economic hardship in past year | 2.0 | 2.8 | 3.2 | .028 |
| Past Year Substance Misuse (any) at Baseline and Follow-Up | ||||
| Prescription opioids | 92.5% | 89.2% | 86.6% | .552 |
| at follow-up | 39.6% | 46.0% | 43.3% | .828 |
| Buprenorphine | 39.6% | 46.0% | 22.7% | .014 |
| at follow-up | 18.9% | 24.3% | 15.5% | .488 |
| Methadone | 26.4% | 40.5% | 27.8% | .286 |
| at follow-up | 9.4% | 16.2% | 8.3% | .386 |
| Prescription benzodiazepines | 62.3% | 64.7% | 62.9% | .967 |
| at follow-up | 24.5% | 40.5% | 32.0% | .272 |
| All other drugs | 66.0% | 78.4% | 83.5% | .049 |
| at follow-up | 26.4% | 37.8% | 52.6% | .007 |
| Injection drug use | 34.0% | 35.1% | 30.9% | .871 |
| at follow-up | 9.4% | 16.2% | 19.6% | .269 |
| Past Month Self-Help Group Attendance | ||||
| Any AA/NA attendance (baseline) | 35.9% | 46.0% | 27.8% | .130 |
| at follow-up | 56.6% | 62.2% | 62.9% | .742 |
| Past Year Mental Health | ||||
| Anxiety (baseline) | 30.2% | 64.9% | 68.0% | <.001 |
| at follow-up | 64.2% | 75.7% | 66.0% | .473 |
| Past Year Criminal Justice System Involvement | ||||
| Any incarceration (baseline) | 79.3% | 70.3% | 41.2% | <.001 |
| at follow-up | 47.2% | 51.4% | 29.9% | .027 |